Date: 2015-07-21
Type of information: Services contract
Compound:
Company: Axxam (Italy) Bayer (Germany)
Therapeutic area: Technology - Services
Type agreement: services contract
Action mechanism:
Disease:
Details: * On July 21st, 2015, Axxam announced that the company has entered into a multi-year collaboration agreement with Bayer HealthCare. The aim of this collaboration is to provide high level services to support Bayer’s commitment to discover new therapies for diseases with high unmet medical need.
This collaboration agreement follows a relationship between the two companies started more than ten years ago with the provision of cell-based and biochemical assays by Axxam amenable to use in ultra HTS systems. The collaboration will leverage Axxam’s strong expertise in assay development for genome derived targets, compound screening and hit-to lead support and will also provide Bayer access to Axxam’s innovative assay technologies.
Financial terms:
Latest news:
